File S1 - Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells

Contains the following Supporting Information files: Table S1: List of healthy samples as controls. Table S2: List of patient samples for clinical validation. Clinico-pathological characteristics are provided for patients with metastatic lung or breast cancer who provided samples for CTC enumeration. Samples may be serially obtained from a single patient and these are indicated by the patient number. C: Cycle, D: Day. Post sutent pre AC samples are stated to be <3 weeks post-treatment. Figure S1: EpCAM staining of enriched cell populations. (A) Immunostaining with EpCAM-FITC and CD45-APC antibodies. (B) Flow cytometry analysis of EpCAM/CD45 cell populations. Scale bar: 20 µm. Figure S2: CTC images displaying variation in EMT biomarker expression. (A) CK+ cells can either be E-cadherin+ or E-cadherin- on breast CTCs. (B) CK+ cells can either be Vimentin+ or Vimentin- on breast CTCs. Scale bar: 20 µm. Figure S3: Scattered plot obtained with flow cytometry analysis. Potassium iodide staining of enriched samples to determine viability. Figure S4: Flow cytometry analysis of CD44-FITC/CD24-APC cell populations. (DOC)